Foundation for Entry into the Energy & Electronics and Bio-Medical Fields
First written in FY2016. 5 of 6 entries say "Advanced", first in FY2018. Latest entry: FY2025.
The whole theme swung hardest in 2017: 1 of 7 companies on the "Worse" side.
2 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「Entered into an agreement with KAKEN PHARMACEUTICAL CO.,LTD. for the exclusive marketing rights to a “silk elastin sponge wound sheet for skin defects” using the functional protein silk elastin, with sales scheduled to begin in fiscal 2025 after obtaining regulatory approval and reimbursement coverage.」
In the bio-medical field, the Company has entered into an exclusive marketing rights agreement for a silk elastin wound-healing product and plans to begin sales in fiscal 2025, indicating progress toward commercialization. - FY2023AdvancedAnnual report
「June 2022: Established Fujifilm Sanyo Chemical Healthcare Co., Ltd. through a joint investment with 富士フイルム Co., Ltd.」
In the healthcare field, including bio-medical applications, progress has been made toward establishing a new company through a joint investment with 富士フイルム. - FY2021AdvancedAnnual report
「One of the achievements of research and development during the consolidated fiscal year was the installation of the next-generation lithium-ion battery, the “All-Polymer Battery,” developed jointly with APB, Inc., an affiliate of the Company, in an autonomous underwater vehicle (Autonomous Underwater Vehicle) being developed by Kawasaki Heavy Industries,Ltd., followed by demonstration testing and successful completion of the initial performance tests.」
In the energy and electronics field, the All-Polymer Battery was installed in an actual vehicle for demonstration testing and passed the initial performance tests. - FY2019AdvancedAnnual report
「In the bio-medical field, we invested in Delta-Fly-Pharma Co., Ltd. and will pursue joint research on new anticancer drugs. In the energy and electronics field, we invested in APB, Inc., a technology venture focused on lithium-ion batteries, and will advance the development of a new lithium-ion battery.」
In the bio-medical field, progress has been made through investment in Delta-Fly-Pharma and joint research on anticancer drugs, while in the energy and electronics field, investment in APB and development of a new lithium-ion battery are advancing. - FY2018AdvancedAnnual report
「Several elemental technologies for a new lithium-ion battery with high electrical capacity, developed jointly with universities and other institutions, have reached the stage where their application to battery systems is feasible. Using these technologies, we are now considering the commercialization of a new lithium-ion battery system, among other initiatives.」
In the energy and electronics field, elemental battery technologies have reached the stage where they can be applied to battery systems, and work is advancing toward commercialization. - FY2016First statedAnnual report
「In addition, we will build a beachhead for new businesses in fields where market growth is expected, namely the energy and electronics and bio-medical fields.」
The energy and electronics and bio-medical fields have been identified as areas with growth potential, with the goal of building a beachhead for new businesses.